Factor VIII biosimilar (Amega Biotech)

凝血因子VIII生物类似药 (Amega Biotech)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameFactor VIII biosimilar (Amega Biotech)

Drug Alias Name重组因子VIII生物仿制药 (Amega Biotech)Recombinant factor VIII (Amega Biotech)凝血因子VIII生物仿制药 (Amega Biotech)

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Recombinant coagulation factor

Mechanisms of ActionCoagulation factor VIII replacementsCoagulation factor X stimulantsBlood coagulation pathway activation

TargetsCoagulation factor X

Therapy Area/IndicationsHemophilia B

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPending (Clinical)

Highest Status in ChinaN/A

Originator CompaniesAmega Biotech

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesAmega Biotech

Active IndicationsN/A

Inactive IndicationsHemophilia B

ATC CodeB02BD02